when the first dose was administered at 6 weeks. It was also recommended that this schedule be reviewed in the light of new data that may become available [11]. While available data from developing countries in Asia and Africa suggest that efficacy of both available vaccines is lower in the second year of life, data presented by Madhi et al. and Cunliffe et al., in this supplement now show a lower efficacy of Rotarix™ in the second year of life when given in a 10, 14 weeks schedule, as compared to a 6, 10, 14 weeks schedule. A recent

report from a cohort study in India showed that reinfection with rotavirus is more common than previously believed and that the rate of protection Modulators against subsequent episodes of rotavirus diarrhoea of Imatinib cost any severity is lower than has been previously reported [14]. The authors suggest that these data indicate the need for increasing the dose or number of doses of vaccine to induce optimal protection in this setting. These and other data on efficacy and effectiveness of the vaccine administered in different schedules and ages, new data on the actual age when vaccines scheduled for delivery at 6,

10 and 14 weeks are delivered, as well as the age of the first episode GS-1101 chemical structure and subsequent episodes of severe rotavirus diarrhoea, would be crucial in defining the optimal age and schedule for immunization in developing countries in Africa and Asia. Finally, the decreased efficacy of the two vaccines in the second year of life, observed ADAMTS5 in the trials in Africa and Asia, raise a question about the need for a booster dose of the vaccine. However, the current recommendations restricting the use of the vaccines in children above 32 weeks would need to be addressed in planning any such studies to evaluate the benefits and risks of a booster dose. In view of the increased

risk of intussusception observed with the older rhesus reassortant rotavirus vaccine (Rotashield®), the trials with the newer rotavirus vaccines restricted its use to younger infants in whom the natural risk of intussusception is lower. Since intussusception was more often associated with the first dose, delivery of the first dose was restricted to children 6–12 weeks (RotaTeq®) or 6–13 weeks (Rotarix™) [15] and [16] of age and the labelled indications restrict the use of the vaccines to children less than 24 or 32 weeks of age. Consequently, the WHO recommendations were to deliver the first dose of either vaccine by 15 weeks of age and the last dose by 32 weeks of age [11]. The age restrictions for the delivery of vaccine are a programmatic challenge in developing countries in Africa and Asia.